Form 4 for LSTA LISATA THERAPEUTICS, INC.
Accepted 2021-12-10 00:00:00 ET · period of report 2021-12-08 · accession 0001078274-21-000006 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021-12-10 | 2021-12-08 | LSTA | MYERS STEVEN S | Dir | P - Purchase | $0.89 | +33.8K | 146.8K | +30% | +$30.1K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-12-08 | P | A | 33,785 | $0.89 | 146,839 | D | — | — | (F1) The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.8802 to $0.9000, inclusive. The reporting person undertakes to provide Caladrius Biosciences, Inc., any security holder of Caladrius Biosciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. (F2) Represents 37,735 unvested restricted stock awards granted under Issuer's 2018 Equity Incentive Compensation plan, which will vest on January 11, 2022. |